STOCK TITAN
  1. Home
  2. Sec-filings
  3. BRTX
  4. [8-K] BioRestorative Therapies, Inc. Reports Material Event

BioRestorative (NASDAQ: BRTX) details 2025 executive pay and bonuses

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

BioRestorative Therapies, Inc. reported that its Compensation Committee approved cash bonuses for executive officers for the year ended December 31, 2025, and presented an updated Summary Compensation Table.

For 2025, CEO Lance Alstodt received salary of $596,666, a discretionary cash bonus of $300,000 and total compensation of $2,409,167. VP of Research and Development Francisco Silva received salary of $566,666, a $287,500 discretionary bonus and total compensation of $2,322,916. CFO Robert Kristal received salary of $343,750, a $140,000 discretionary bonus and total compensation of $801,750. The bonuses relate to 2025 services and are to be paid in 2026.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
CEO 2025 salary $596,666 Lance Alstodt 2025 base salary
CEO 2025 bonus $300,000 Discretionary bonus for 2025 services, paid in 2026
CEO 2025 total compensation $2,409,167 Lance Alstodt total 2025 compensation
VP R&D 2025 salary $566,666 Francisco Silva 2025 base salary
VP R&D 2025 bonus $287,500 Discretionary bonus for 2025 services, paid in 2026
VP R&D 2025 total compensation $2,322,916 Francisco Silva total 2025 compensation
CFO 2025 salary $343,750 Robert Kristal 2025 base salary
CFO 2025 bonus $140,000 Discretionary bonus for 2025 services, paid in 2026
Summary Compensation Table financial
"The following Summary Compensation Table sets forth all compensation earned"
discretionary bonus financial
"The 2025 Bonus amount represents a discretionary bonus in consideration of 2025 services"
FASB ASC Topic 718-Stock Compensation financial
"computed in accordance with stock-based accounting rules (FASB ASC Topic 718-Stock Compensation)"
aggregate grant date fair value financial
"Amounts reflect the aggregate grant date fair value of grants made in the fiscal year"
Understanding 8-K Material Events →
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
___________________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report: May 1, 2026
(Date of earliest event reported)
 
BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)
 
Nevada
001-37603
30-1341024
(State or Other Jurisdiction of Incorporation)
(Commission File No.)
(IRS Employer Identification Number)
 
40 Marcus Drive, Melville, New York
    11747
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant's telephone number, including area code: (631) 760-8100
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
___
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
___
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
___
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
___
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)

Name of each exchange on which registered
Common Stock, $0.0001 par value
BRTX
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ____
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___
 
 

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
(f)
On May 1, 2026, the Compensation Committee of the Board of Directors of BioRestorative Therapies, Inc. (the “Company”) approved cash bonuses for the Company’s executive officers for the year ended December 31, 2025, as set forth below in the updated Summary Compensation Table.   
Summary Compensation Table
The following Summary Compensation Table sets forth all compensation earned in all capacities during the fiscal years ended December 31, 2025 and 2024 by (i) our principal executive officer, and (ii) our two most highly compensated executive officers, other than our principal executive officer, who were serving as an executive officer as of December 31, 2025 and whose total compensation for the 2025 fiscal year, as determined by Regulation S-K, Item 402, exceeded $100,000 (the individuals falling within categories (i) and (ii) are collectively referred to as the Named Executive Officers):
Name and Principal Position
 
Year
 
 
Salary
 
 
Bonus
 
 
Stock Awards(1)
 
 
Option Awards(1)
 
 
All Other Compensation
 
 
Total
 
Lance Alstodt
 
 
2025
 
 
$
596,666
 
 
$
300,000
 (2)
 
$
-
 
 
$
1,512,500
 
 
$
-
 
 
$
2,409,167
 
Chief Executive Officer
 
 
2024
 
 
$
539,583
 
 
$
275,000
 (3)
 
$
-
 
 
$
500,000
 
 
$
-
 
 
$
1,314,583
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Francisco Silva
 
 
2025
 
 
$
566,666
 
 
$
287,500
 (2)
 
 
-
 
 
$
1,468,750
 
 
 
-
 
 
$
2,322,916
 
VP, Research and Development
 
 
2024
 
 
$
514,583
 
 
$
262,500
 (3)
 
$
-
 
 
$
450,000
 
 
$
-
 
 
$
1,227,083
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Robert Kristal
 
 
2025
 
 
$
343,750
 
 
$
140,000
 (2)
 
$
-
 
 
$
318,000
 
 
$
-
 
 
$
801,750
 
Chief Financial Officer
 
 
2024
 
 
$
293,752
 
 
$
90,000
 (3)
 
$
-
 
 
$
300,000
 
 
$
-
 
 
$
683,752
 
 
(1)
Amounts reflect the aggregate grant date fair value of grants made in the fiscal year computed in accordance with stock-based accounting rules (FASB ASC Topic 718-Stock Compensation). Assumptions used in the calculations of these amounts are included in Note 6 to our consolidated financial statements included in this Annual Report.
(2)
The 2025 Bonus amount represents a discretionary bonus in consideration of 2025 services which is to be paid in 2026.
(3)
The 2024 Bonus amount represents a discretionary bonus in consideration of 2024 services which was paid in 2025.
 
 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: May 1, 2026
BIORESTORATIVE THERAPIES, INC.
 
 
 
By:/s/ Robert Kristal
 
Robert Kristal
 
Chief Financial Officer
 
 
 
 
 
 
                    
 
 
 
 
 
 
                    
 
 
 

0001505497 false US 0001505497 2026-05-01 2026-05-01

Source: View Original Filing on SEC EDGAR

FAQ

What executive compensation changes did BRTX disclose for 2025?

BioRestorative Therapies approved 2025 discretionary cash bonuses for its top executives and updated its Summary Compensation Table, showing salary, bonus and equity awards for 2025 and 2024, including total compensation for the CEO, VP of Research and Development, and CFO.

How much total compensation did BRTX’s CEO receive for 2025?

CEO Lance Alstodt’s 2025 total compensation was $2,409,167, including $596,666 in salary and a $300,000 discretionary cash bonus for 2025 services, plus previously granted equity awards valued under stock-based accounting rules in the company’s financial statements.

What were the 2025 compensation details for BRTX’s VP of Research and Development?

Francisco Silva, VP of Research and Development, had 2025 total compensation of $2,322,916, consisting of $566,666 in salary, a $287,500 discretionary cash bonus for 2025 services, and previously granted equity awards measured using FASB ASC Topic 718 stock-based compensation rules.

How was BRTX’s CFO compensated in 2025?

CFO Robert Kristal’s 2025 total compensation was $801,750, including $343,750 in salary and a $140,000 discretionary bonus for 2025 services, along with option or stock awards and other elements valued consistent with the company’s stock-based compensation accounting policies.

When will the 2025 executive bonuses at BRTX be paid?

The 2025 bonus amounts disclosed for BioRestorative Therapies’ executives are described as discretionary cash bonuses granted in consideration of 2025 services, and the filing states that these 2025 bonuses are to be paid during 2026 following the end of the performance year.

How does BRTX calculate the value of stock and option awards in its compensation table?

The company reports the aggregate grant date fair value of stock and option awards using FASB ASC Topic 718 stock-based compensation rules, relying on assumptions described in Note 6 to its consolidated financial statements included in its related annual reporting documents.

Filing Exhibits & Attachments

3 documents

Other Documents